Drug Profile
House dust mite allergy immunotherapy tablet - Stallergenes Greer plc
Alternative Names: Actair; House dust mite allergy immunotherapy - Stallergenes Greer plc; House dust mite SLIT; House dust mite sublingual immunotherapy; Oralair Mites; S-524101; STAGR 320; STG 320Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Stallergenes SA
- Developer Shionogi; Stallergenes Greer plc
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic asthma; Perennial allergic rhinitis
Most Recent Events
- 02 Jun 2021 Stallergenes Greer announces intention to launch house dust mite allergy immunotherapy tablet for Perennial allergic rhinitis in selected European countries
- 31 May 2021 Registered for Perennial allergic rhinitis in European Union (Sublingual)
- 20 Nov 2018 Stallergenes announces intention to submit BLA to the US FDA as well as for additional marketing authorizations in European and international markets for Perennial allergic rhinitis